Alinia Shortage: What Providers and Prescribers Need to Know in 2026

Nitazoxanide (Alinia) is an essential antiprotozoal medication for managing giardiasis and cryptosporidiosis in immunocompetent patients. While the FDA does not currently list nitazoxanide in active shortage, prescribers continue to hear from patients who cannot find it at their local pharmacies. This practical guide helps clinicians understand the access landscape and manage patient expectations effectively.

Current FDA Status: No Active Shortage as of 2026

The FDA Drug Shortage database does not identify nitazoxanide (Alinia) as currently in shortage. This means there are no documented manufacturing disruptions, active recalls, or distribution-level supply failures affecting this drug nationally.

However, 'not in shortage' and 'readily available' are not the same thing. The de facto access challenge for nitazoxanide stems from pharmacy-level stocking practices, not supply chain failure. Prescribers should set realistic expectations with patients that finding this medication may require effort.

Why Patients Struggle to Find Nitazoxanide

The access problem for nitazoxanide is structural. Consider these contributing factors:

Low and episodic demand. Parasitic GI infections are not high-volume diagnoses in the U.S. Most pharmacies fill very few nitazoxanide prescriptions per month, so routine stocking is not cost-effective for them.

High brand cost. Brand Alinia retails for $1,350–$1,600 per 6-tablet course. Holding expensive, slow-moving inventory is a financial disincentive for many pharmacies.

Recently introduced generic. The generic nitazoxanide received FDA approval in 2020. While it has expanded the manufacturing base and lowered cost, it has not yet achieved ubiquitous stocking at chain pharmacies.

Short course, no refills. The standard regimen is just 3 days (6 tablets). There's no recurring prescription stream to motivate pharmacies to maintain standing stock.

Clinical Context: When Is Nitazoxanide Indicated?

Nitazoxanide (Alinia) is FDA-approved for:

Diarrhea caused by Giardia lamblia in patients 1 year and older (suspension) or 12 years and older (tablets)

Diarrhea caused by Cryptosporidium parvum in immunocompetent patients 1 year and older (suspension) or 12 years and older (tablets)

It is NOT indicated and has not been shown effective for cryptosporidiosis in HIV-positive or immunodeficient patients. For giardiasis, it's an important alternative to nitroimidazoles, particularly when metronidazole resistance or intolerance is a concern. The active metabolite tizoxanide is in vitro eight times more active against susceptible Giardia strains than metronidazole and twice as active against resistant isolates.

Evidence-Based Alternatives When Nitazoxanide Is Unavailable

If a patient cannot access nitazoxanide in a clinically appropriate timeframe, consider the following alternatives based on the indication:

For giardiasis (G. lamblia):

Tinidazole 2 g PO single dose — highest clinical cure rate per meta-analysis; avoid in first trimester of pregnancy; alcohol restriction 72h

Metronidazole 250 mg TID or 500 mg BID for 5–7 days — WHO first-line; widely stocked; alcohol restriction throughout and 48h post-course

Albendazole 400 mg QD x 5 days — comparable efficacy to metronidazole in RCTs; fewer GI side effects; no alcohol restriction; also treats other parasites

Paromomycin 25–35 mg/kg/day in 3 divided doses for 5–10 days — preferred in pregnancy (poor systemic absorption); less effective than other agents

For cryptosporidiosis (C. parvum) in immunocompetent patients:

The infection is typically self-limiting in immunocompetent hosts, resolving within 1–2 weeks. Supportive care with hydration and electrolyte replacement is the primary approach. If pharmacologic treatment is needed, nitazoxanide remains the drug of choice; there is no widely studied substitute.

Dosing Reference for Nitazoxanide

Adults and adolescents (≥12 years): 500 mg PO BID x 3 days with food (tablets)

Children 4–11 years: 200 mg (10 mL) suspension PO BID x 3 days with food

Children 1–3 years: 100 mg (5 mL) suspension PO BID x 3 days with food

Tablets should not be used in children 11 years and younger — the tablet strength (500 mg) exceeds pediatric dosing recommendations

Strategies for Prescribers to Improve Patient Access

Write for the generic: Specify 'nitazoxanide' (not just Alinia) to maximize pharmacy options; include 'substitution permitted'

Identify a reliable pharmacy: Develop a relationship with a local hospital outpatient pharmacy or independent pharmacy that stocks antiparasitic medications. Direct patients there preferentially.

E-prescribe to multiple pharmacies simultaneously if your EHR system allows

Recommend medfinder for providers — a service that contacts pharmacies near patients to find which ones can fill the prescription. This can save patients significant time, especially for medications like Alinia that aren't universally stocked.

Patient Cost Assistance Programs

For commercially insured patients, the Romark Alinia Co-pay Program can reduce out-of-pocket cost to as little as $0 per prescription (maximum savings of $300 per fill). Advise patients to visit alinia.com/savings/tablets. For uninsured patients, the generic nitazoxanide with a GoodRx coupon at approximately $223 is the most accessible option.

Key Takeaways for Prescribers

No FDA shortage of nitazoxanide in 2026, but de facto access barriers are real

Generic nitazoxanide is therapeutically equivalent to Alinia — prescribe generically to expand options

For giardiasis, tinidazole (single dose) or metronidazole are first-line alternatives that are widely available

For C. parvum in immunocompetent patients, the infection is often self-limiting — balance treatment need against access difficulty

Direct patients to medfinder.com/providers for pharmacy finding assistance